Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis

Yuchen Wu 1,2, Cong Li 1,2, Jiang Zhao 1,2, Li Yang 1,2, Fangqi Liu 1,2, Hongtu Zheng 1,2, Zhimin Wang 3* and Ye Xu 1,2*

Abstract

Background: Recent evidence indicates that inflammatory parameters could be useful to predict metastasis from colorectal cancer. However, their roles in predicting chemotherapy response and prognosis in patients with synchronous colorectal liver metastasis (CLM) are unknown.

Methods: The clinical data and baseline laboratory parameters of 55 patients with synchronous CLM were retrospectively reviewed. All patients underwent palliative resection of the primary tumor and oxaliplatin-based chemotherapy. Two indices of systemic inflammation were reviewed—neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR)—preoperatively and before the second cycle of chemotherapy. Associations between prognostic variables and tumor response, progression, and survival were investigated.

Results: NLR < 4 and PLR < 150 were correlated with better disease control (p = 0.024 and 0.026, respectively). In univariate analysis, elevated NLR and PLR were significant prognostic factors for poor overall survival (OS) and progression-free survival (PFS). In multivariate analysis, PLR (p = 0.027), age (p = 0.018), resection of liver metastases (p = 0.017), and lactate dehydrogenase level (p = 0.011) were independent predictors of PFS, while resection of liver metastases was the only independent predictor of OS (p = 0.002). In addition, when patients were divided into groups according to changes in NLR and/or PLR, reduced NLR and PLR were associated with improved disease control (p = 0.038 and 0.025, respectively). Normalization of NLR also was associated with improved PFS.

Conclusions: NLR and PLR are potentially useful clinical biomarkers to predict chemotherapy response in patients with synchronous CLM. PLR also may be useful to predict PFS in these patients.

Keywords: PLR, NLR, Synchronous colorectal liver metastasis, Prognosis, Chemotherapy response
Background

Colorectal cancer (CRC) is the third most common cancer worldwide and the fifth most common in China [1]. It is also the fifth most common cause of cancer-related death. Although there have been remarkable improvements in the treatment and management of CRC, outcomes remain poor, with approximately 40% of patients who undergo curative surgery dying from their disease [2], especially those with distant metastases.

In patients with synchronous colorectal liver metastasis (CLM), radical resection is the only curative therapy [3], which can increase 5-year survival up to 71% [4]. However, in unresectable or potentially resectable CLM, chemotherapy is a paramount consideration. Studies have shown that chemotherapy regimens can downstage 15 to 50% of patients from unresectable to resectable cancer [5]. However, there are numerous patients who cannot benefit from adjuvant chemotherapy, and identifying and developing biomarkers able to distinguish such patients is important.

Fortunately, several parameters for predicting survival in patients with CRC have been identified, including such inflammatory-based prognostic parameters as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), white blood cell count, and platelet count [6–9]. NLR, calculated as neutrophil count divided by lymphocyte count, is the most frequently reported marker and is involved in almost every stage of CRC [6, 10–12]. Increased NLR is associated with worse outcomes and insensitive response to adjuvant chemotherapy or radiotherapy [13, 14]. PLR, calculated as platelet count divided by lymphocyte count, is also gaining attention in some research [8].

It is unclear whether both indices are associated with chemotherapy response in patients with synchronous CLM treated with oxaliplatin-based chemotherapy after resection of primary lesions. Therefore, in this study, we examined the correlations of NLR and PLR with chemotherapy sensitivity and prognosis in these patients.

Methods

Patient selection, treatment, and follow-up

We retrospectively reviewed a database of patients treated in the Department of Colorectal Surgery at the Shanghai Cancer Center from June 2008 to December 2013. Patients who met the following criteria were selected: (a) initially diagnosed as having synchronous CLM; (b) evaluated as having potentially resectable cancer before any treatment; (c) Eastern Cooperative Oncology Group (ECOG) status <2; (d) available and complete clinical records, including pathologic diagnosis, treatment strategy, follow-up information, and laboratory data; and (e) treated with first-line chemotherapy. The exclusion criteria included patients who had either malignant tumors in other organs or systematic inflammatory or hematologic disease. Patients with complications from the primary tumor, such as obstruction or hemorrhage, also were excluded.

A total of 55 patients were finally included in the study. All patients underwent R0 resection of the primary tumor followed by oxaliplatin-based chemotherapy, including mFOLFOX6 (folic acid/fluorouracil plus oxaliplatin) or XELOX (capecitabine plus oxaliplatin). The duration from surgery to chemotherapy was within 1 month.

Laboratory tests and imaging examinations were performed every 3 months. The Response Evaluation Criteria in Solid Tumors was applied for evaluation of disease status. Radical hepatectomy of metastases was conducted if the patient had reached complete response (CR) or partial response (PR). Four patients who had reached stable disease (SD) after chemotherapy also underwent radical hepatectomy, as their metastases had contracted but they did not meet the baseline criteria of PR.

Parameters evaluated

The following parameters were evaluated: sex, age, number of liver metastases, CLM resection, and chemotherapy protocol. Several pathologic parameters, including size, pathologic subtype, differentiation, location, tumor invasion, nodal status, lymphovascular invasion, perineural invasion, extranodal tumor deposits, and microsatellite instability, also were evaluated. Laboratory parameters, including NLR, PLR, alkaline phosphatase (ALP) level, lactate dehydrogenase (LDH) level, carcinoembryonic antigen level, and CA199 level, also were assessed.

The number of liver metastases was categorized according to the criteria between minor and major lesions [15]. Regarding pathologic diagnosis, expression of MLH1, MSH2, MLH6, and PMS2 was routinely evaluated. Any deficiency was considered as deficient mismatch repair. We used the X-tile Software (http://medicine.yale.edu/lab/rimm/research/) to determine the cutoff values of NLR and PLR based on the minimum p values from the log-rank chi-square statistics (Additional file 1). Finally, the cutoff values of NLR and PLR were set at 4 and 150, respectively, which were also in accordance with previous researches [6, 16, 17]. All parameters were evaluated preoperatively and before the second cycle of chemotherapy. Other parameters were presented according to the normal value range at our hospital.

Statistical analysis

Progression-free survival (PFS) was defined as the duration from primary tumor resection to disease progression, while overall survival (OS) was defined as the duration from surgery to the date of death or the last date of follow-up.

All statistical analyses were performed by using SPSS version 20.0 (IBM Corporation, Armonk, NY, USA). Fisher’s exact test was used to compare chemotherapy response among groups. Survival curves were plotted by using...
the Kaplan-Meier method and analyzed by using the log-rank test. Univariate and multivariate analyses to identify prognostic predictors were performed by using Cox proportional hazard models. A $p$ value of $<0.05$ was considered as significant in all analyses.

**Results**

**Patient characteristics**

All of the patients’ clinicopathologic features are summarized in Table 1. Patients were predominantly male (64%), and the median age was 59 years. Almost half of the patients had more than three liver metastases. Regarding the chemotherapy regimen, 21 patients (38%) received mFOLFOX6, while 34 (62%) received XELOX. Of these patients, 12 (22%) underwent radical resection of liver metastases.

According to the pathologic results, the median maximum size of the primary lesion was 4 cm, and almost all of the lesions (91%) were identified as adenocarcinoma. Twenty-five patients (45%) suffered from colon cancer, while 30 (55%) suffered from rectal cancer. Most of the lesions (98%) reached an invasive depth of T3 to T4 with local nodal metastasis (80%). Furthermore, lymphovascular invasion, perineural invasion, and extranodal tumor deposits were almost evenly distributed, and most of the patients were proficient mismatch repair.

With regard to laboratory data, 41 patients (75%) had a low NLR, and 31 (56%) had a low PLR. Other biochemical parameters, such as ALP and LDH levels, were normal in most of the patients. On the contrary, most of the patients had elevated serum carcinoembryonic antigen and CA199 levels.

**NLR and PLR with regard to chemotherapy response**

Objective chemotherapy response, including CR and PR, did not differ significantly between groups divided by preoperative NLR and PLR ($p = 0.051$ and 0.195, respectively; Table 2). However, disease control, including CR, PR, and SD, was significantly better in groups with comparatively lower preoperative NLR ($56–21\%$, $p = 0.024$) and PLR ($61–29\%$, $p = 0.026$) (Table 2).

| Table 1 Characteristic variable | No. of patients (%) |
|---------------------------------|---------------------|
| **Clinical background**          |                     |
| Sex                             | Male 35 (64)         |
|                                 | Female 20 (36)       |
| Age (years)                     | <60 28 (51)          |
|                                 | ≥60 27 (49)          |
| Number of liver metastasis      | ≤3 27 (49)           |
|                                 | >3 28 (51)           |
| Liver metastasis resection      | No 43 (78)           |
|                                 | Yes 12 (22)          |
| First-line chemotherapy         | FOLFOX 21 (38)       |
|                                 | XELOX 34 (62)        |
| **Surgical pathology**          |                     |
| Maximum size (cm)               | ≤4 29 (53)           |
|                                 | >4 26 (47)           |
| Pathology                       | Adenocarcinoma 50 (91) |
|                                 | Mucinous or signet-ring carcinoma 5 (9) |
| Differentiation                 | G1–G2 33 (60)        |
|                                 | G3–G4 22 (40)        |
| Location                        | Colon 25 (45)        |
|                                 | Rectum 30 (55)       |
| Tumor stage (T)                 | 2 1 (2)              |
|                                 | 3 13 (24)            |
|                                 | 4 41 (74)            |
| Nodal status (N)                | 0 11 (20)            |
|                                 | 1 19 (35)            |
|                                 | 2 25 (45)            |
| Lymphovascular invasion         | No 25 (45)           |
|                                 | Yes 30 (55)          |
| Perineural invasion             | No 28 (51)           |
|                                 | Yes 27 (49)          |
| Extranodal tumor deposits       | No 30 (55)           |
|                                 | Yes 25 (45)          |
| MSI status                      | dMMR 4 (7)           |
|                                 | pMMR 51 (93)         |
| Blood biochemical test          |                     |
| NLR                             | <4 41 (75)           |
|                                 | ≥4 14 (25)           |
| PLR                             | <150 31 (56)         |
|                                 | ≥150 24 (44)         |
| ALP                             | Normal 46 (84)       |
|                                 | Elevated 9 (16)      |

| Table 1 Characteristic variable (Continued) | No. of patients (%) |
|---------------------------------------------|---------------------|
| LDH                                         | Normal 44 (80)      |
|                                             | Elevated 11 (20)    |
| Serum CA199 level                           | Normal 20 (36)      |
|                                             | Elevated 35 (64)    |
| Serum CEA level                             | Normal 12 (22)      |
|                                             | Elevated 43 (78)    |
Prognostic factors
Median OS was significantly longer in patients with NLR < 4 and PLR < 150, which was 24 to 56 months in the NLR groups (p = 0.008) and 27 to 56 months in the PLR groups (p = 0.017) (Fig. 1a, b). Results of median PFS coincided with those of OS, which was 7 to 23 months in the NLR groups (p = 0.01) and 8 to 26 months in the PLR groups (p = 0.002) (Fig. 1c, d).

Tables 3 and 4 show the results of univariate and multivariate analyses of various parameters evaluated in this study. Univariate analysis revealed that number of metastases >3, no resection of liver metastases, and elevated NLR and PLR were significantly associated with worse OS. However, according to multivariate analysis, only resection of liver metastases was a significant independent prognostic factor (p = 0.002).

With regard to PFS, the parameters mentioned above, together with elevated LDH level and patient age <60 years, correlated with worse PFS. Multivariate analysis revealed that age (p = 0.018), resection of liver metastases (p = 0.017), LDH level (p = 0.011), and PLR (p = 0.027) were significant independent prognostic factors.

Normalization of NLR and PLR before cycle 2 and correlations with PFS and OS
Patients were categorized into three groups as follows: group 1, patients with NLR < 4 or PLR < 150 at baseline (n = 41 and 31, respectively); group 2, patients with elevated NLR and PLR had worse prognosis. a, b Patients with higher NLR and PLR tended to have worse overall survival (p = 0.008 and p = 0.017). c, d Patients with higher NLR and PLR tended to have worse progression-free survival (p = 0.01 and p = 0.002).
NLR ≥ 4 or PLR ≥ 150 at baseline, which decreased before cycle 2 of chemotherapy (n = 8 and 11, respectively); and group 3, patients with a higher NLR or PLR, which did not decrease before cycle 2 of chemotherapy. As presented in Table 5, patients with normalization of NLR or PLR before cycle 2 of chemotherapy showed improved disease control (p = 0.038 and 0.025, respectively). However, no significant change in objective chemotherapy response was observed, which coincided with the results of preoperative NLR and PLR.

Finally, we conducted subgroup analysis according to changes in NLR and PLR between two stages of the treatment process (Fig. 2a, b). Patients with normalization of NLR had significantly better PFS than those with a high NLR that did not decrease (p = 0.002). However, although a tendency of better PFS was detected in patients with

### Table 3 Prognostic factors associated with OS and PFS in univariate analysis

| Prognosis variables                  | Overall survival | Progression-free survival |
|--------------------------------------|------------------|---------------------------|
|                                      | p value          | HR (95% CI)               | p value          | HR (95% CI)               |
| Gender, male/female                  | 0.986            | 1.009 (0.384–2.651)       | 0.579            | 1.197 (0.635–2.254)       |
| Age, ≥60/ <60                        | 0.109            | 2.142 (0.844–5.440)       | 0.007*           | 0.397 (0.203–0.775)       |
| Number of metastasis, ≥3/ <3         | 0.049*           | 1.323 (1.011–1.809)       | 0.015*           | 2.167 (1.159–4.054)       |
| Liver metastasis resection, yes/no   | 0.001*           | 0.028 (0.012–0.049)       | 0.005*           | 0.313 (0.138–0.710)       |
| Chemotherapy, FOLFOX/XELOX           | 0.735            | 0.855 (0.346–2.113)       | 0.891            | 0.925 (0.522–1.759)       |
| Maximum size (cm), ≤4/ >4            | 0.261            | 2.385 (0.525–10.84)       | 0.620            | 1.164 (0.638–2.123)       |
| Pathology, adenocarcinoma/mucinous    | 0.261            | 2.385 (0.525–10.84)       | 0.737            | 1.225 (0.376–3.993)       |
| Differentiation, G1–G2/G3–G4          | 0.930            | 2.385 (0.525–10.84)       | 0.302            | 1.386 (0.745–2.580)       |
| Location, colon/rectum               | 0.421            | 1.159 (0.809–1.659)       | 0.446            | 1.265 (0.691–2.314)       |
| Tumor stage (T)                      |                  |                           |                  |
| T2/T3                                | 0.835            | 6.231 (0.926–52.51)       | 0.054            | 7.826 (0.962–63.66)       |
| T2/T4                                | 0.554            | 1.339 (0.460–4.251)       | 0.094            | 2.410 (0.899–4.843)       |
| Nodal status (N)                     |                  |                           |                  |
| N0/N1                                | 0.496            | 0.637 (0.174–2.330)       | 0.811            | 0.908 (0.412–2.001)       |
| N0/N2                                | 0.759            | 0.859 (0.326–2.265)       | 0.396            | 0.396 (0.360–1.483)       |
| Lymphovascular invasion, no/yes      | 0.399            | 0.683 (0.281–1.658)       | 0.867            | 0.950 (0.520–1.735)       |
| Perineural invasion, no/yes          | 0.289            | 1.613 (0.667–3.899)       | 0.064            | 1.775 (0.967–30257)       |
| Extranodal tumor deposits, no/yes    | 0.340            | 1.542 (0.633–3.755)       | 0.549            | 1.201 (0.660–2.186)       |
| MSI status, pMMR/MMR                | 0.371            | 0.606 (0.202–1.817)       | 0.542            | 0.673 (0.189–2.404)       |
| NLR, ≥4/ <4                          | 0.013*           | 3.182 (1.277–7.933)       | 0.017*           | 2.284 (1.156–4.948)       |
| PLR, ≥150/ <150                      | 0.024*           | 2.954 (1.155–7.551)       | 0.002*           | 2.535 (1.339–4.779)       |
| ALP, elevated/normal                 | 0.905            | 0.927 (0.267–3.217)       | 0.374            | 1.449 (0.640–3.282)       |
| LDH, elevated/normal                 | 0.257            | 1.810 (0.650–5.041)       | 0.008            | 2.673 (1.292–5.528)       |
| Serum CA199 level, elevated/normal   | 0.343            | 1.640 (0.590–4.560)       | 0.700            | 1.135 (0.596–2.158)       |
| Serum CEA level, elevated/normal     | 0.487            | 1.552 (0.450–5.351)       | 0.669            | 1.183 (0.548–2.553)       |

* A p value <0.05 was considered statistically significant

### Table 4 Prognostic factors associated with OS and PFS in multivariate analysis

| Prognosis variables                  | Overall survival | Progression-free survival |
|--------------------------------------|------------------|---------------------------|
|                                      | p value          | HR (95% CI)               | p value          | HR (95% CI)               |
| Age, <60/ ≥60                        | 0.016*           | 2.437 (1.162–4.847)       | 0.002*           | 2.373 (1.162–4.847)       |
| Number of metastasis, <3/ ≥3         | 0.781            | 0.843 (0.251–2.823)       | 0.582            | 1.309 (0.501–3.423)       |
| Liver metastasis resection, yes/no   | 0.002*           | 0.003 (0.012–0.033)       | 0.017*           | 0.180 (0.058–0.554)       |
| NLR, ≥4/ <4                          | 0.477            | 1.511 (0.212–2.064)       | 0.520            | 1.334 (0.312–1.801)       |
| PLR, ≥150/ <150                       | 0.510            | 1.447 (0.231–2.070)       | 0.027*           | 2.591 (0.166–8.986)       |
| LDH, normal/elevated                 | 0.011*           | 0.310 (0.125–0.768)       |

* A p value <0.05 was considered statistically significant
reduced PLR, the difference was not significant ($p = 0.329$). Moreover, there was no significant difference in OS (data not shown).

Discussion

To our knowledge, this is the first study to evaluate the associations of NLR and PLR with prognosis and chemotherapy response in patients with synchronous CLM who underwent palliative resection of the primary tumor followed by oxaliplatin-based chemotherapy. Our results support the use of NLR and PLR as markers to predict chemotherapy response and prognosis, which would help to evaluate the possibility of secondary surgery for CLM as well as to elucidate the survival rates in such patients.

Immune cells act closely with tumor development, while NLR reflects systematic inflammation. Several studies have revealed the prognostic role of NLR in patients with CRC [6]. Although its mechanism has not been clarified, several investigations have deduced its close correlations with interleukin 6, interleukin 8, vascular epidermal growth factor, and other cytokines, which play important roles in tumorigenesis [18–20]. However, most studies focused on the use of NLR as a predictor in advanced CRC. Vauthey first reported that a high NLR independently predicted worse OS in patients with CLM treated with chemotherapy followed by hepatic resection or chemotherapy alone [21]. Other studies focusing on unresectable CLM have achieved similar results indicating NLR as an independent predictor of survival [22, 23]. In our study, we confirmed that a high NLR predicted worse OS and PFS. However, we did not achieve the same result in multivariate analysis, which somewhat conflicts with the studies mentioned above. A possible reason might be the difference in the study group we enrolled, which was confined to synchronous CLM with palliative resection of the primary lesion. However, the close correlation between NLR and chemotherapy response, i.e., the possibility of metastasis resection, might cover the statistical difference in the multivariate analysis model.

The mechanism of PLR in tumorigenesis might be derived from the role of platelets in promoting angiogenesis, adhesion, and invasion by increasing the production of vascular epidermal growth factor and transforming growth factor.

### Table 5 Chemotherapy response rate according to the alteration in NLR and PLR before the second cycle of treatment

| Response | NLR | PLR |
|----------|-----|-----|
| Group 1 ($N=41$) | Group 2 ($N=8$) | Group 3 ($N=6$) | p value | Group 1 ($N=31$) | Group 2 ($N=11$) | Group 3 ($N=13$) | p value |
| Objective response rate (CR + PR), % (cases) | 20% (8) | 25% (2) | 0 (0) | 0.070 | 19% (6) | 18% (2) | 0 (0) | 0.126 |
| Disease control rate (CR + PR + SD), % (cases) | 56% (23) | 38% (3) | 0 (0) | 0.038* | 61% (19) | 45% (5) | 15% (2) | 0.025* |

NLR: group 1, <4; group 2, ≥4 → <4; group 3, ≥4 → ≥4. PLR: group 1, <150; group 2, ≥150 → <150; group 3, ≥150 → ≥150

*A $p$ value ≤0.05 was considered statistically significant. (group 2 compared with group 3)

Fig. 2 Changes in PFS with normalization of NLR and PLR. a Patients with normalization of NLR had better PFS ($p = 0.002$) than those with stable NLR levels. b PFS of patients with normalization of PLR did not differ ($p = 0.329$).
factor-beta in a tumor environment [24]. Meanwhile, cytokines and chemokines released from platelets facilitate other immune cells, including neutrophils and lymphocytes, to infiltrate into tumor lesions and trigger inflammatory progress [25]. Contrary to the wide study of NLR in CRC, fewer studies have focused on PLR. Xia demonstrated that in metastatic CRC, NLR was superior to PLR for predicting prognosis; in fact, NLR was the only independent predictor [26]. This finding was confirmed by another study in which preoperative NLR and derived NLR, but not PLR, were associated with worse OS and cancer-specific survival [27]. However, in patients with liver-only colorectal metastases and hepatectomy, Mudan found the reverse result, in which the prognostic effect of preoperative PLR was superior to that of NLR [28]. In our study, we also found that patients with a high preoperative PLR had worse PFS and OS and that only PLR was an independent predictor of PFS. However, its impact on OS was not observed, which might also be due to the interaction with metastasis resection. Overall, we demonstrated a better prognostic value of PLR than NLR.

NLR and PLR also have been reported as markers of chemotherapy response. In Clarke’s research, they enrolled two independent cohorts with unresectable CRC who received first-line palliative chemotherapy and found that normalization of NLR after one cycle of chemotherapy resulted in improved PFS [24]. Meanwhile, in a study of patients with advanced or recurrent unresectable CRC who received oxaliplatin-based combination chemotherapy, Kitayama also found better disease control in those with a low NLR [25]. Our results are in agreement with these previous studies showing that patients with a low NLR benefit more from first-line oxaliplatin-based chemotherapy. Patients with a dramatic decrease in NLR after one cycle of chemotherapy also demonstrated improved disease control and PFS, as its reduction might reflect the sensitivity to chemotherapy. Moreover, we found the same results with regard to PLR. However, we only found a tendency of improved PFS in those with normalization of PLR, which might be due to the limited number of patients in our study.

The current study had several limitations that are common in retrospective investigations. With an increased sample size and expanded follow-up, the impact of NLR and PLR in such patients would be ascertained. In addition, we did not evaluate the adverse reactions from chemotherapy, which might have affected the patients’ quality of life and survival. Finally, we did not consider or standardize the subsequent therapeutic strategy, which correlated closely with OS.

Conclusions
In conclusion, our results suggest that preoperative NLR and PLR and their normalization might be good markers for better disease control in patients with synchronous CLM. PLR was better than NLR for predicting PFS in this study. Based on these findings, we have a better understanding of these patients, which may help to guide their therapeutic strategy.

Additional file

Additional file 1: X-tile plots of NLR and PLR to OS and PFS, respectively. X-axis represents all cutoff values applied from low to high (left to right) to define the subsets. Brighter pixels indicate a stronger association between markers and prognosis. Cutoff values were defined in the brightest pixels (marked by the bold black dots). A and B. Cutoff values of NLR were 3.9 to PFS and 3.7 to OS, respectively. C. Cutoff value of PLR to PFS ranged from about 135 to 220. D. Cutoff value of PLR to OS was 150.1. (TIF 3184.64 kb)

Abbreviations
ALP: Alkaline phosphatase; CLM: Colorectal liver metastasis; CR: Complete response; CRC: Colorectal cancer; ECOG: Eastern Cooperative Oncology Group; LDH: Lactic dehydrogenase; mFOLFOX6: Folic acid/fluorouracil plus oxaliplatin; NLR: Neutrophil-to-lymphocyte ratio; OS: Overall survival; PFS: Progression-free survival; PLR: Platelet-to-lymphocyte ratio; PR: Partial response; SD: Stable disease; XELOX: Capecitabine plus oxaliplatin

Acknowledgements
Not applicable.

Funding
Not applicable.

Availability of data and materials
The datasets during and/or analyzed during the current study are available from the corresponding authors on reasonable request.

Authors’ contributions
YW and CL carried out the data acquisition, participated in the data analysis, and drafted the manuscript. JZ and LY carried out the literature research and participated in the data analysis. FL and HZ participated in the design of the study and performed the statistical analysis. ZW and YX conceived of the study and performed the statistical analysis. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
This study was approved by the Ethic Committee of Fudan University Shanghai Cancer Center, and written informed consent was obtained from every participant.

Author details
1Department of Oncology, Shanghai Medical College, Shanghai 200032, China. 2Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China. 3Department of Genetics, Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai 201203, China.

Received: 11 August 2016 Accepted: 7 November 2016
Published online: 16 November 2016

References
1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.
2. Oliphant R, Nicholson GA, Horgan PG, Molloy RG, McMillan DC, Morrison DS. Contribution of surgical specialization to improved colorectal cancer survival. Br J Surg. 2013;100:1388–95.

3. Ito K, Govindarajan A, Ito H, Fong Y. Surgical treatment of hepatic colorectal metastasis: evolving role in the setting of improving systemic therapies and ablative treatments in the 21st century. Cancer J. 2010;16:103–10.

4. Alosa TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, Curley SA, Zorzi D, Abdalla EK. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg. 2006;141:460–6. discussion 6-7.

5. Adam R, Delvart V, Pascal G, Valeau A, Castaigne D, Azoulay D, Giaccchetti S, Paule B, Kunstlinger F, Ghemard O, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–57. discussion 57-8.

6. Malletzis G, Giacometti M, Kennedy RH, Athanasious T, Aziz O, Jenkins JT. The emerging role of neutrophil to lymphocyte ratio in determining colorectal cancer treatment outcomes: a systematic review and meta-analysis. Ann Surg Oncol. 2014;21:398–46.

7. Wan S, Lai I, Myers RE, Li B, Hyslop T, London J, Chatterjee D, Palazzo JP, Buikert AL, Zhang K, et al. Preoperative platelet count associates with survival and distant metastasis in surgically resected colorectal cancer patients. J Gastrointest Cancer. 2013;44:293–304.

8. Szakandera J, Pichler M, Absenger G, Armering F, Weissmueller M, Schaberl-Moser R, Samonigg H, Konrapt P, Stojakovic T, et al. The elevated preoperative platelet to lymphocyte ratio predicts decreased time to recurrence in colon cancer patients. Ann J Surg. 2014;208:210–4.

9. Feng JF, Huang Y, Chen QX. The combination of platelet count and neutrophil lymphocyte ratio is a predictive factor in patients with esophageal squamous cell carcinoma. Transl Oncol. 2014;7:632–7.

10. Galizia G, Lieto E, Zamboli A, De Vita A, Castellano P, Romano C, Auricchio C, Cardella F, De Stefano L, Orditura M. Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers: a propensity score-matched analysis. Surgery. 2015;158:112–20.

11. Malletzis G, Giacometti M, Askari A, Nachiappan S, Kennedy RH, Faiz OD, Aziz O, Jenkins JT. A preoperative neutrophil to lymphocyte ratio of 3 predicts disease-free survival after curative elective colorectal cancer surgery. Ann Surg. 2014;260:287–92.

12. Shin JS, Suh KW, Oh SY. Preoperative neutrophil to lymphocyte ratio predicts survival in patients with T1-2N0 colorectal cancer. J Surg Oncol. 2015;112:654–7.

13. Kautzhammer M, Rouvinov K, Ariad S, Man S, Wolfish S, Pinsk I, Sztkar I, Charkovsky T, Lavenkov K. A study of inflammation-based predictors of tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Oncology. 2013;85:27–32.

14. Kim IY, You SH, Kim YW. Neutrophil-lymphocyte ratio predicts pathologic tumor response and survival after preoperative chemoradiation for rectal cancer. BMC Surg. 2014;14:94.

15. Akgul O, Cetinkaya E, Eroso M, Tuz M, Role of surgery in colorectal cancer liver metastases. World J Gastroenterol. 2014;20:6113–22.

16. Jankova L, Dent OF, Chan C, Chapuis P, Clarke SJ. Preoperative neutrophil /lymphocyte ratio predicts overall survival but does not predict recurrence or cancer-specific survival after curative resection of node-positive colorectal cancer. BMC Cancer. 2013;13:442.

17. Absenger G, Szakandera J, Stotz M, Postimayr U, Pichler M, Ress AL, Schabeler-Moser R, Lobnner H, Samonigg H, Genger A. Preoperative neutrophil-to-lymphocyte ratio predicts clinical outcome in patients with stage II and III colon cancer. Anticancer Res. 2013;33:4591–4.

18. Kim YW, Kim SK, Kim CS, Kim IY, Cho MY, Kim NK. Association of serum and intratumoral cytokine profiles with tumor stage and neutrophil lymphocyte ratio in colorectal cancer. Anticancer Res. 2014;34:3481–7.

19. Pine JK, Morris E, Hutchins GG, West NP, Jayne DG, Quirke P, Prasad KR. Systemic neutrophil-to-lymphocyte ratio in colorectal cancer: the relationship to patient survival, tumour biology and local lymphocytic response to tumour. Br J Cancer. 2015;113:204–11.

20. Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, et al. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer. 2015;112:1088–97.

21. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol. 2009;16:634–22.

22. Chua WK, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011;104:1288–95.

23. Kaneko M, Nozawa H, Sasaki K, Hongo K, Hiyoshi M, Tada N, Murono K, Nitei T, Kawai K, Sunami E, et al. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in advanced colorectal cancer patients receiving oxaliplatin-based chemotherapy. Oncology. 2012;82:261–8.

24. Suzuki K, Aiera K, Ueda M, Kitajima M. The influence of platelets on the promotion of invasion by tumor cells and inhibition by antplatelet agents. Pancreas. 2004;29:132–40.

25. Jenne CN, Utantia R, Kubes P. Platelets: bridging hemostasis, inflammation, and immunity. Int J Lab Hematol. 2013;35:254–61.

26. He W, Yin C, Guo G, Jiang C, Wang F, Ouu H, Chen X, Rong R, Zhang B, Xia L. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer. Med Oncol. 2013;30:439.

27. Neal CP, Caims V, Jones MJ, Massood MM, Nana GR, Mann CD, Garcea G, Dennison AR. Prognostic performance of inflammation-based prognostic indices in patients with resectable colorectal liver metastases. Med Oncol. 2015;32:144.

28. Neofytou K, Smyth EC, Giakoustidis A, Khan AZ, Cunningham D, Mudan S. Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor. Med Oncol. 2014;31:239.